Clinical trials: Dermatitis Eczema
Dermatitis, Atopic
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
This study is a 2-part (parts A and B) study.The primary objective of the study is to evaluate the efficacy of 611 in Chinese Children with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07767253
- Testing
- 611
- Where
- 5 sites in China
- Volunteers
- 246 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis
This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.
- Trial name
- NCT06162507
- Testing
- CM310
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of…
- Trial name
- NCT05527964
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers
This will be a phase I, single center, randomized, vehicle-controlled, blinded study comparing two dosage strengths of CRx-197 cream, nortriptyline, an active comparator (0.1% mometasone) and placebo (the active ingredient free…
- Trial name
- NCT00721331
- Testing
- nortriptyline HCl + loratadine, nortriptyline HCl, mometasone furoate
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zalicus
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- ADvocate2 (NCT04178967)
- Testing
- Lebrikizumab
- Where
- 89 sites in United States, Bulgaria and 6 more
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD)
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07336940
- Testing
- ENV-294 Capsule
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Enveda Therapeutics
Atopic Dermatitis
CT 327 in the "Atopy Patch Test" Model
A Randomized, Double-Blind, Phase I, Single-Center Study on the Efficacy and Safety of CT 327 in the Atopy Patch Test model.
- Trial name
- CT327 AD01-09 (NCT01368315)
- Testing
- CT327 application, Active comparator, No intervention
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Creabilis SA
Atopic Dermatitis
Probiotic on Atopic Dermatitis in Infant
The clinical trial will be carried out in China Medical University Hospital. The overall plan is a double-blind trial. All recruited 3 months-3 years old atopic dermatitis (AD) patients are divided into two groups, 50 in each…
- Trial name
- NCT05286047
- Testing
- Bifidobacterium longum CCFM1029
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Glac Biotech Co., Ltd
Atopic Dermatitis
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)
Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).
- Trial name
- ECZTRA 1 (NCT03131648)
- Testing
- Tralokinumab
- Where
- 123 sites in United States, France and 3 more
- Volunteers
- 802 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis
This is a study of safety, tolerability, pharmacokinetics and pharmacodynamics of AM1030-CREAM in patients with Atopic Dermatitis.
- Trial name
- NCT02379910
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- AnaMar AB
Atopic Dermatitis
Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis
The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week
- Trial name
- NCT06026891
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis
CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis
This is a phase III study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.
- Trial name
- NCT02965118
- Testing
- PAC-14028 cream 1.0%, PAC-14028 cream Vehicle
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Amorepacific Corporation
Atopic Dermatitis, Skin Condition
Clinical Study of Partially Hydrolysed Protein Infant Formula on Trans-epidermal Water Loss (TEWL)
This is a single-centre, prospective, randomized, open-label, controlled trial of 200 infants 42±7 days of age. Subjects will be randomized to one of two open label feeding intervention group: Intact Cow's Milk Protein Formula…
- Trial name
- NCT04763512
- Testing
- Intact Cow's Milk Protein Formula, Partially Hydrolysed Whey Formula
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Atopic Dermatitis
Phase 2 Study of KHK4577
This study is an randomized double-blind placebo-controlled study to evaluate the efficacy and the safety of oral KHK4577 for 6 weeks in patients with atopic dermatitis. Pharmacokinetics of KHK4577 will also be assessed.
- Trial name
- NCT02004119
- Testing
- KHK4577
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Atopic Dermatitis
The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis
This clinical trial will study the effects of PUFA supplementation during pregnancy and lactation period on fatty acid composition in human milk and plasma of the mothers and the clinical outcome of atopic dermatitis in infants…
- Trial name
- NCT01936194
- Testing
- DHA+EPA, High Olive Oil, DHA
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mead Johnson Nutrition
Atopic Dermatitis
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.
- Trial name
- NCT00316602
- Testing
- IMVAMUNE
- Where
- 22 sites in United States, Mexico
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Atopic Dermatitis (Eczema)
The Effects of a Botanical Moisturizer, an Oral Supplement, and an Unscented Soap on Eczema and Itch
The purpose of this study is to examine the effects of a botanical moisturizer, an oral supplement, and an unscented soap on eczema severity, itch, mood, and various skin measures (such as skin hydration) in those with mild to…
- Trial name
- NCT06819709
- Testing
- Botanical Moisturizer + Oral Supplement + Unscented Soap
- Where
- Poland
- Volunteers
- 35 people
- Sponsor
- Codex Labs Corporation
Atopic Dermatitis
A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients
- Trial name
- NCT04369846
- Testing
- GM-XANTHO onitment
- Where
- 4 sites in Taiwan
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Xantho Biotechnology Co., LTD
Moderate to Severe Atopic Dermatitis
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to…
- Trial name
- REZOLVE-AD (NCT06136741)
- Testing
- Rezpegaldesleukin
- Where
- 107 sites in United States, Australia and 8 more
- Volunteers
- 396 people
- Sponsor
- Nektar Therapeutics
Atopic Dermatitis
A First-in-Human Study of QY211 Gel in Adult Subjects
This is a phase Ia/Ib,Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Single and Multiple Topical Doses of…
- Trial name
- NCT05843422
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.